secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001493152-24-006773
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06
-----------------------------------------------------------------------

- Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.
- Issues unregistered Series A/B warrants for 7,203,504 shares at $1.06; Series A expire 18 months, Series B May 2028.
- Net proceeds for Phase 3 prep of PF614, debt repayment (Oct/Nov 2023), and general corporate.
- Placement agent H.C. Wainwright gets $200k fee and 252,123 warrants at $1.6375.
- Waiver from Oct 2023 SPA requires full note repayment with premium post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/0001493152-24-006773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-006773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer